Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC an
Allogene Therapeutics Announces Q2 Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics with a Buy and maintains $10 price target.
Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
Allogene Therapeutics' Stability Threatened by Banking Sector Turmoil
RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target
RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.
Allogene Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 115.29% RBC Capital → $10 Reiterates Outperform → Outperform 02/27/2024 72.23% JP Morgan $9 → $
Allogene Therapeutics: Redefining LBCL Treatment With Innovative ALPHA3 Trial and Promising Cema-cel Therapy
Allogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value Growth
Allogene Therapeutics (ALLO) Gets a Buy From RBC Capital
Allogene Therapeutics Files $500 Million Mixed Shelf
Allogene Therapeutics (ALLO) filed a registration statement Thursday for the potential sale of up to $500 million of securities from time to time. The filing covers the sale of the company's common st
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
Earnings Call Summary | Allogene Therapeutics(ALLO.US) Q4 2023 Earnings Conference
The following is a summary of the Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript:Financial Performance:Allogene Therapeutics ended Q4 2023 with a solid cash balance of $448.7 mill
Allogene Therapeutics Files for $500M Mixed Shelf
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops
Allogene Therapeutics (ALLO) reported late Thursday a Q4 net loss of $0.51 per diluted share, narrowing from $0.67 a year ago. Analysts polled by Capital IQ expected a loss of $0.45. Collaboration rev
Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.46) by 10.87 percent. This is a 23.88 percent increase over losses
Allogene Therapeutics: Co Expects a Decrease in Cash, Cash Equivalents, and Investments of Approximately $190M in 2024 >ALLO
Allogene Therapeutics: Co Expects a Decrease in Cash, Cash Equivalents, and Investments of Approximately $190M in 2024 >ALLO
No Data